<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

Recently, it was suggested that consensus molecular subtyping (CMS) may aide in predicting response to EGFR inhibitor (cetuximab) therapies. We recently identified that <i>APC</i> and <i>TP53</i> as two tumor suppressor genes, when mutated, may enhance cetuximab sensitivity a...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramya Thota, Mingli Yang, Lance Pflieger, Michael J. Schell, Malini Rajan, Thomas B. Davis, Heiman Wang, Angela Presson, Warren Jack Pledger, Timothy J. Yeatman
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
colorectal cancer
<i>APC</i>
<i>TP53</i>
mutations
CMS classification
EGFR inhibitors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/83b5ca18ff454dabb1beb852018f41e2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/83b5ca18ff454dabb1beb852018f41e2

Similar Items